57 related articles for article (PubMed ID: 18399167)
1. [Effect of CYP2C19 gene polymorphism on efficacy of thalidomide-based regimens for the treatment of multiple myeloma].
Li YH; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):651-4. PubMed ID: 18399167
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma.
Li Y; Hou J; Jiang H; Wang D; Fu W; Yuan Z; Chen Y; Zhou L
Haematologica; 2007 Sep; 92(9):1246-9. PubMed ID: 17666363
[TBL] [Abstract][Full Text] [Related]
3. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
He XX; Zhao YH; Hao YT
Zhonghua Nei Ke Za Zhi; 2004 Jan; 43(1):13-5. PubMed ID: 14990013
[TBL] [Abstract][Full Text] [Related]
4. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.
Vangsted AJ; Søeby K; Klausen TW; Abildgaard N; Andersen NF; Gimsing P; Gregersen H; Vogel U; Werge T; Rasmussen HB
BMC Cancer; 2010 Aug; 10():404. PubMed ID: 20684753
[TBL] [Abstract][Full Text] [Related]
5. Influence of cytochrome P450 2C19 gene variations on pharmacokinetic parameters of thalidomide in Japanese patients.
Matsuzawa N; Nakamura K; Matsuda M; Ishida F; Ohmori S
Biol Pharm Bull; 2012; 35(3):317-20. PubMed ID: 22382316
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity.
Burns KE; Goldthorpe MA; Porteus F; Browett P; Helsby NA
Cancer Chemother Pharmacol; 2014 Mar; 73(3):651-5. PubMed ID: 24519754
[TBL] [Abstract][Full Text] [Related]
7. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
[TBL] [Abstract][Full Text] [Related]
8. Association of poor metabolizers of cytochrome P450 2C19 with head and neck cancer and poor treatment response.
Yadav SS; Ruwali M; Shah PP; Mathur N; Singh RL; Pant MC; Parmar D
Mutat Res; 2008 Sep; 644(1-2):31-7. PubMed ID: 18644391
[TBL] [Abstract][Full Text] [Related]
9. The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects.
Jiang ZP; Shu Y; Chen XP; Huang SL; Zhu RH; Wang W; He N; Zhou HH
Eur J Clin Pharmacol; 2002 May; 58(2):109-13. PubMed ID: 12012142
[TBL] [Abstract][Full Text] [Related]
10. CYP2C19 polymorphism has no correlation with the efficacy and safety of thalidomide in the treatment of immune-related bowel disease.
Feng R; Xu PP; Chen BL; Mao R; Zhang SH; Qiu Y; Zeng ZR; Chen MH; He Y
J Dig Dis; 2020 Feb; 21(2):98-103. PubMed ID: 31916702
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
[TBL] [Abstract][Full Text] [Related]
12. Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.
Seo T; Nagata R; Ishitsu T; Murata T; Takaishi C; Hori M; Nakagawa K
Pharmacogenomics; 2008 May; 9(5):527-37. PubMed ID: 18466100
[TBL] [Abstract][Full Text] [Related]
13. Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.
Okudaira K; Furuta T; Shirai N; Sugimoto M; Miura S
Aliment Pharmacol Ther; 2005 Feb; 21(4):491-7. PubMed ID: 15710002
[TBL] [Abstract][Full Text] [Related]
14. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.
Kasamatsu T; Saitoh T; Ino R; Gotoh N; Mitsui T; Shimizu H; Matsumoto M; Sawamura M; Yokohama A; Handa H; Tsukamoto N; Murakami H
Hematol Oncol; 2017 Dec; 35(4):711-718. PubMed ID: 27405747
[TBL] [Abstract][Full Text] [Related]
16. [Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma].
DU J; Yuan ZG; Zhang CY; Fu WJ; Jiang H; Chen BA; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2009 Oct; 30(10):649-53. PubMed ID: 19954656
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation.
Elmaagacli AH; Koldehoff M; Steckel NK; Trenschel R; Ottinger H; Beelen DW
Bone Marrow Transplant; 2007 Oct; 40(7):659-64. PubMed ID: 17680025
[TBL] [Abstract][Full Text] [Related]
18. Effect of CYP2C19 polymorphism on response to bortezomib-based therapy in multiple myeloma patients.
Goel L; Gupta P; Kumar L; Velpandian T; Singh A; Luthra K; Gupta YK
Am J Med Sci; 2024 Jul; 368(1):18-24. PubMed ID: 38561047
[TBL] [Abstract][Full Text] [Related]
19. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
[TBL] [Abstract][Full Text] [Related]
20. Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
Krejci M; Gregora E; Straub J; Minarik J; Scudla V; Adam Z; Krivanova A; Pour L; Zahradova L; Buchler T; Mayer J; Hajek R
Ann Hematol; 2011 Dec; 90(12):1441-7. PubMed ID: 21380511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
